Tenax Therapeutics (NASDAQ:TENX) Earns “Outperform” Rating from William Blair
Tenax Therapeutics (NASDAQ:TENX – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at William Blair in a report released on Monday,RTT News reports. Separately, ...
Yahoo Finance8d
Tenax Therapeutics Announces $25 Million Private Placement
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company ...
Nasdaq8d
Tenax Therapeutics Announces FDA Acceptance of Expanded Phase 3 LEVEL Study and Initiation of Global LEVEL-2 Trial for TNX-103 Development
Tenax Therapeutics, Inc. announced that the FDA has accepted their plan to expand the Phase 3 LEVEL study of TNX-103 (oral levosimendan), increasing patient enrollment from 152 to 230 to enhance ...
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initiate Second Global Phase 3 Study, ...
manilatimes11d
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
The live and archived webcast of the presentation will be accessible from the Company's investor relations webpage. Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company ...